N
Nicolò Borsellino
Researcher at University of Palermo
Publications - 74
Citations - 1184
Nicolò Borsellino is an academic researcher from University of Palermo. The author has contributed to research in topics: Regimen & Chemotherapy. The author has an hindex of 20, co-authored 66 publications receiving 1085 citations.
Papers
More filters
Journal ArticleDOI
Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II Study
Vittorio Gebbia,Francesco Giuliani,Evaristo Maiello,Giuseppe Colucci,Francesco Verderame,Nicolò Borsellino,Gaetano Mauceri,Michele Caruso,Maria Lina Tirrito,Matteo Valdesi +9 more
Journal ArticleDOI
Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity
Nicolò Borsellino,Benjamin Bonavida,Gennaro Ciliberto,Carlo Toniatti M.D.,Salvatore Travali,Natale D'Alessandro +5 more
TL;DR: The human prostate carcinoma PC‐3 cell line, derived from a metastatic tumor and lacking androgen receptors, represents a useful model to investigate drug resistance.
Journal Article
Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study.
Vittorio Gebbia,Antonio Testa,Nicolò Borsellino,G. Mauceri,F. Varvara,Maria Lina Tirrito,D. Sambataro,G. Fallica +7 more
TL;DR: Single agent gemcitabine at the dose of 1000 mg/m2 on a weekly schedule is active, at least in terms of objective response rate and tumor-related symptoms palliation, against pretreated urothelial carcinoma with good tolerability.
Journal ArticleDOI
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale
Vittorio Gebbia,Domenico Galetta,Michele Caruso,Francesco Verderame,G. Pezzella,Matteo Valdesi,Nicolò Borsellino,Giuseppe Pandolfo,E. Durini,Massimo Rinaldi,Michele Loizzi,Nicola Gebbia,Roberto Valenza,Maria Lina Tirrito,F. Varvara,Giuseppe Colucci +15 more
TL;DR: The data reject the 'worst drug rule' hypothesis of sequential treatments in NSCCL at least with the combination used in this study, and indicate that the combination of vinorelbine and cisplatin and that of gemcitabine and cascplatin are equivalent in terms of median TTP and OS, although the vinorlbine-cisplatin regimen is associated with a higher ORR.
Journal ArticleDOI
Cancer patient-centered home care: a new model for health care in oncology
Paolo Tralongo,Francesco Ferraù,Nicolò Borsellino,Francesco Verderame,Michele Caruso,Dario Giuffrida,Alfredo Butera,Vittorio Gebbia +7 more
TL;DR: Patient-centered home care is a new model of assistance, which may be integrated with more traditional hospital-centered care especially in selected groups of informed and trained patients, and takes into account the emotional and psychosocial aspects of the disease.